Reliance Global Plans Majority Stake In AI Breath Diagnostics Firm Scentech

(RTTNews) - Reliance Global Group (RELI) announced on Wednesday that it has signed a non-binding term sheet to buy a majority stake in Scent Medical Technologies Ltd., a company working on AI tools to spot disease-related molecular markers in human breath.

If this deal goes through, it would mark the first asset under Ezra International Group, which is Reliance's new tech-focused division.

Scent Medical's lineup includes VOX, a platform for non-invasive pancreatic cancer risk assessments, and VocTracer, designed for the early detection of healthcare-associated infections and antimicrobial resistance.

Just a heads up, all these products are still in development and need clinical validation plus regulatory approval before they can hit the market.

RELI is currently trading at $0.58, down $0.02 or 4.32 percent on the Nasdaq.